Neurocrine Biosciences, Inc. Aktie News

SAN DIEGO , June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's techno...

Tokyo, Japan and Cambridge, UK, 3 June 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner, Neurocrine Biosciences (“Neurocrine”) has dosed the first patient in its Phase 3 registrational program of NBI-1117568 (NBI-'568) as a potential treatment for schizophrenia, resulting in a payment of US$15 million to Nxera (Clinical Trial ID: NCT06963034)....

KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning Improvements were seen as early as Wee...

Tokyo, Japan and Cambridge, UK, 29 May 202 5 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting in Scottsdale, Arizona.

SAN DIEGO , May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia, which showed a significant improvement in symptoms and overall severity and highlighted new data on the safety and tolerability of the treatment. NBI-1117568 is the first and only investigational oral mu...

The top five biotech stocks today have several commonalities. Among them are strong ratings.

One-Year Data Show Lasting Reductions in Glucocorticoid Doses and Improvements in Clinical Outcomes with CRENESSITY™ (crinecerfont) in Pediatric Patients with Classic Congenital Adrenal Hyperplasia SAN DIEGO , May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present new data from the Phase 3 CAHtalyst™ Pediatric study showing lasting reductions in...

Patients Treated with INGREZZA® (valbenazine) Capsules Reported Continued Improvements in Functional and Health-Related Quality of Life Measures Findings Presented at 2025 International Society for Pharmacoeconomics and Outcomes Research Conference SAN DIEGO , May 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new analyses from a Phase 4...